No Data
Enveda Gains Backing From Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
Sanofi Target Raised to EUR125 From EUR100 by Intron Health
Sanofi Raised to Buy From Hold by Intron Health
Duvakitug, co-developed by Sanofi (SNY.US) and Teva (TEVA.US), is expected to enter phase 3 clinical trials in the second half of the year.
Sanofi (SNY.US) and Teva (TEVA.US) recently announced the detailed results obtained from their jointly developed monoclonal antibody duvakitug in the phase 2 clinical trial RELIEVE UCCD.
Sanofi Obtains Regulatory Approval for Blood Cancer Drug Sarclisa in Japan
Press Release: Sarclisa Approved in Japan for Patients With Newly Diagnosed Multiple Myeloma
